{
    "clinical_study": {
        "@rank": "142886", 
        "arm_group": [
            {
                "arm_group_label": "High energy formula", 
                "arm_group_type": "Active Comparator", 
                "description": "High energy formula (Similac)"
            }, 
            {
                "arm_group_label": "Standard formula", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard formula"
            }
        ], 
        "brief_summary": {
            "textblock": "High energy formula more positively affect growth in infants with congenital heart disease\n      compared to standard formula"
        }, 
        "brief_title": "High Energy Formula Feeding in Infants With Congenital Heart Disease", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Growth Failure", 
            "Neurodevelopmental Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Failure to Thrive", 
                "Heart Diseases", 
                "Heart Defects, Congenital"
            ]
        }, 
        "detailed_description": {
            "textblock": "Infants with congenital heart disease (CHD) usually show growth retardation as they can not\n      intake enough calorie due to fluid restriction. We hypothesize that high energy formula more\n      positively affect growth in infants with congenital heart disease compared to standard\n      formula"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  infants >35 weeks of gestational age\n\n          -  infants with CHD\n\n          -  \u0130nfants fed with formula feeding\n\n        Exclusion Criteria:\n\n          -  Major congenital abnormalities except CHD\n\n          -  infants could not be fed enterally"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "6 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850784", 
            "org_study_id": "132/2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "High energy formula", 
                "description": "The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)", 
                "intervention_name": "High energy formula", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "High energy formula (Similac)"
            }, 
            {
                "arm_group_label": "Standard formula", 
                "description": "The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)", 
                "intervention_name": "Standard formula", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Standard formula"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Congenital heart disease, Growth,Neurodevelopment", 
        "lastchanged_date": "May 8, 2013", 
        "location": {
            "contact": {
                "last_name": "Nazan N Do\u011fan, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Ankara", 
                    "country": "Turkey"
                }, 
                "name": "Sami Ulus CH"
            }, 
            "investigator": {
                "last_name": "Nazan N Do\u011fan", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "official_title": "High Energy Formula Feeding in Infants With Congenital Heart Disease", 
        "overall_contact": {
            "email": "dilekdilli2@yahoo.com", 
            "last_name": "Dilek Dilli, Assoc Prof", 
            "phone": "00903126243"
        }, 
        "overall_official": {
            "affiliation": "Sami Ulus CH", 
            "last_name": "Dilek Dilli", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Weight gain", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850784"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dr. Sami Ulus Children's Hospital", 
            "investigator_full_name": "Dilek Dilli", 
            "investigator_title": "Assoc Prof", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Neurodevelopmental evaluation will be assessed by Bayley-II Scale at corrected age of 12-18 months.", 
            "measure": "Neurodevelopmental evaluation", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "source": "Dr. Sami Ulus Children's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dr. Sami Ulus Children's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}